Navigation Links
Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced clinical trial results related to Halozyme's clinical stage drug, pegylated rHuPH20 (PEGPH20). The results were presented at the 2011 EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer", taking place October 27-29 in Brussels, Belgium.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

Today's presentation focused on translational biomarker and pharmacodynamic results from the two Phase 1 dose-finding studies in patients with advanced solid tumors that were unresponsive to prior therapies. Study 101 investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, and Study 102 investigated multiple-dosing of PEGPH20 in combination with dexamethasone.  

Results

The pharmacodynamics of PEGPH20 were first evaluated by measuring the concentration of circulating hyaluronan (HA) catabolites. HA plasma levels increased, in a dose-dependent manner, after PEGPH20 administration. Freeing up of HA by PEGPH20 is consistent with the expected mechanism of PEGPH20.

Tumor imaging from subsets of patients pre- and post-administration of PEGPH20 demonstrated that PEGPH20 treatment rapidly restored tumor perfusion and decreased metabolic activity in tumors. Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) showed that the imaging agent was able to access a pancreatic tumor more easily post-administration of PEGPH20. [18F]-fluorodeoxyglucose positron emission tomogra
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
2. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
3. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
4. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
7. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
8. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
9. Halozyme Receives $5.5 Million Payment From Baxter
10. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
11. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.Y. (PRWEB) August 21, 2014 The ... the first private college in the Mid-Hudson Region to ... will now begin accepting applications from qualified “high-technology” businesses ... “We are very pleased to have been selected for ... Governor Cuomo’s transformative initiative to stimulate economic development in ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that the ... and Mexico currently faces ... approved agents, the anticipated label extension of Boehringer ... of emerging biologics will substantially increase the competitiveness ... IL-5 inhibitors will introduce a new dynamic to the ...
(Date:8/21/2014)... 21, 2014 Mathematic studies at the Program ... and funded by the Jeffrey Epstein VI Foundation , ... be visually identified for elimination. These aggressive cells are the ... shows a topological map of what to look for when ... for while tumor cells can be extracted from biopsy, it,s ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... , COLLEGEVILLE, Pa., Aug. 11 ... WYE ), announced it received notice that the action date for ... Biologics License Application (BLA) for Prevnar ... from September 30, 2009, to December 30, 2009. In response ...
... , , WILMINGTON, Del., Aug. 11 ... appropriate use of drugs, is sponsoring a free Webinar-on-Demand created ... as a role of chief safety officers in healthcare companies. ... at ParagonRx,s website, www.para g onrx.com/experience/webinars/ ...
... Baltimore Convention Center - September 21-23, 2009 ... This summit will attract more than 1,200 experts from more than ... than 100 speakers, including governors, federal officials, and top researchers and ... and human-interest stories. This is your chance to meet and ...
Cached Biology Technology:Wyeth Provides Regulatory Update on Prevnar 13* in the United States 2Wyeth Provides Regulatory Update on Prevnar 13* in the United States 3Wyeth Provides Regulatory Update on Prevnar 13* in the United States 4Wyeth Provides Regulatory Update on Prevnar 13* in the United States 5Wyeth Provides Regulatory Update on Prevnar 13* in the United States 6World Stem Cell Summit to Be Held in Baltimore 2
(Date:8/21/2014)... 2014 , WHERE: , San Diego Convention ... 92101 , WHAT: , Invited and platform ... research in human genetics. Examples of sessions include: ... rare genetic variants in health and disease, the ... sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , Crowdsourced ...
(Date:8/21/2014)... published in the journal Carcinogenesis by researchers ... for the protein adenomatous polyposis coli (APC) in suppressing ... in the U.S. , Lead author Kristi Neufeld, associate ... of the Cancer Biology program at the KU Cancer ... trying to understand the various activities of APC, a ...
(Date:8/21/2014)... international standards process, will be available soon and will ... published in the OnlineFirst version of Nutrition in ... of the American Society for Parenteral and Enteral Nutrition ... of misconnection that can be harmful and even fatal ... join medical devices, components, and accessories to deliver fluids ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3New feeding tube connectors will improve patient safety 2
... report presents a 20-year road map for increasing U.S. resilience ... highly populated area. The report was mostly written prior ... of experts who authored it noted that the Japanese experience ... in a country acknowledged as a leader in implementing earthquake-resilience ...
... Good news for candy and chocolate lovers: they tend ... waist circumferences, and have decreased levels of risk factors for ... study(1) published in Nutrition Research . The findings ... RD, Louisiana State University Agricultural Center, cautions it is all ...
... A new series of events at the New ... solid waste that may offer large cities sustainable alternatives ... in the "Trash Talk" series on Thursday, April 7, ... and biological treatment. Experts will explain how ...
Cached Biology News:US earthquake resilience needs strengthening, says new report 2US earthquake resilience needs strengthening, says new report 3New study shows you can have your candy and eat it too -- without adverse health effects 2
Antibody Purification Specificity: Antibody Purification ...
... Alkaline Phosphatase Conjugation ... Fluorescein Isothiocyanate Conjugation R. Phycoerythrin Conjugation ... Alexa Fluor 488 Conjugation Alexa Fluor ... Rpe-Alexa Fluor 750 Conjugation Apc-Alexa ...
Qa-1 (6A8.6F10)...
Human Cell Line Slides...
Biology Products: